Evolution of DNA aptamers through in vitro metastatic-cell-based systematic evolution of ligands by exponential enrichment for metastatic cancer recognition and imaging.

Metastasis, the capability of tumor cells to spread and grow at distant sites, is the primary factor in cancer mortality. Because metastasis in sentinel lymph nodes suggests the original spread of tumors from a primary site, the detection of lymph node involvement with cancer serves as an important prognostic and treatment parameter. Here we have developed a panel of DNA aptamers specifically binding to colon cancer cell SW620 derived from metastatic site lymph node, with high affinity after 14 rounds of selection by the cell-SELEX (systematic evolution of ligands by exponential enrichment) method. The binding affinities of selected aptamers were evaluated by flow cytometry. Aptamer XL-33 with the best binding affinity (0.7 nM) and its truncated sequence XL-33-1 with 45 nt showed excellent selectivity for recognizing target cell SW620. The binding entity of the selected aptamer has been preliminarily determined as a membrane protein on the cell surface. Tissue imaging results showed that XL-33-1 was highly specific to the metastatic tumor tissue or lymph node tissue with corresponding cancer metastasis and displayed an 81.7% detection rate against colon cancer tissue with metastasis in regional lymph nodes. These results suggest that XL-33-1 has great potential to become a molecular imaging agent for early detection of lymph node tissue with colon cancer metastasis. More importantly, this study clearly demonstrates that DNA ligands selectively recognizing metastatic cancer cells can be readily generated by metastatic-cell-based SELEX for potential applications in metastatic cancer diagnosis and treatment.

[1]  Anna M Wu,et al.  Antibody vectors for imaging. , 2010, Seminars in nuclear medicine.

[2]  L. Gold,et al.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.

[3]  U. Gunnarsson,et al.  Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  Xiaohong Fang,et al.  Recognition of subtype non-small cell lung cancer by DNA aptamers selected from living cells. , 2009, The Analyst.

[5]  J. Szostak,et al.  In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.

[6]  Weihong Tan,et al.  Molecular Recognition of Small‐Cell Lung Cancer Cells Using Aptamers , 2008, ChemMedChem.

[7]  H. Wester,et al.  Molecular imaging targeting peptide receptors. , 2009, Methods.

[8]  I. Fidler,et al.  The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited , 2003, Nature Reviews Cancer.

[9]  Yanling Song,et al.  Identification, Characterization and Application of a G-Quadruplex Structured DNA Aptamer against Cancer Biomarker Protein Anterior Gradient Homolog 2 , 2012, PloS one.

[10]  A D Ellington,et al.  Aptamers as therapeutic and diagnostic reagents: problems and prospects. , 1997, Current opinion in chemical biology.

[11]  Weihong Tan,et al.  Self-assembled, aptamer-tethered DNA nanotrains for targeted transport of molecular drugs in cancer theranostics , 2013, Proceedings of the National Academy of Sciences.

[12]  D. Shangguan,et al.  Development of DNA aptamers using Cell-SELEX , 2010, Nature Protocols.

[13]  F. Ducongé,et al.  Metastasis‐focused cell‐based SELEX generates aptamers inhibiting cell migration and invasion , 2011, International journal of cancer.

[14]  J. Sutcliffe,et al.  In vivo positron emission tomography (PET) imaging with an alphavbeta6 specific peptide radiolabeled using 18F-"click" chemistry: evaluation and comparison with the corresponding 4-[18F]fluorobenzoyl- and 2-[18F]fluoropropionyl-peptides. , 2008, Journal of medicinal chemistry.

[15]  Zhong-xian Lu,et al.  A G‐Quadruplex Aptamer Inhibits the Phosphatase Activity of Oncogenic Protein Shp2 in vitro , 2011, Chembiochem : a European journal of chemical biology.

[16]  M. Skobe,et al.  Lymphatic Vessel Activation in Cancer , 2002, Annals of the New York Academy of Sciences.

[17]  G. V. van Dongen,et al.  Immuno-PET: a navigator in monoclonal antibody development and applications. , 2007, The oncologist.

[18]  Weihong Tan,et al.  Aptamers from cell-based selection for bioanalytical applications. , 2013, Chemical reviews.

[19]  R. Weissleder.  Molecular Imaging in Cancer , 2006, Science.

[20]  S. Jayasena.  Aptamers: an emerging class of molecules that rival antibodies in diagnostics. , 1999, Clinical chemistry.

[21]  Hisataka Kobayashi,et al.  Target-cancer-cell-specific activatable fluorescence imaging probes: rational design and in vivo applications. , 2011, Accounts of chemical research.

[22]  J. Thompson,et al.  The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. , 1997, Nucleic acids research.

[23]  Omid C. Farokhzad,et al.  Current Progress of Aptamer-Based Molecular Imaging , 2014, The Journal of Nuclear Medicine.

[24]  F. Füchtner,et al.  Module-assisted synthesis of the bifunctional labelling agent N-succinimidyl 4-[(18)F]fluorobenzoate ([(18)F]SFB). , 2005, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[25]  Michael Famulok,et al.  Functional aptamers and aptazymes in biotechnology, diagnostics, and therapy. , 2007, Chemical reviews.

[26]  D. Shangguan,et al.  Aptamers evolved from live cells as effective molecular probes for cancer study , 2006, Proceedings of the National Academy of Sciences.

[27]  S. Hirakawa.  From tumor lymphangiogenesis to lymphvascular niche , 2009, Cancer science.

[28]  Mei-Di Hu,et al.  The application of aptamers in cancer research: an up-to-date review. , 2013, Future oncology.

[29]  Clark J Zeebregts,et al.  Current imaging modalities to visualize vulnerability within the atherosclerotic carotid plaque. , 2008, Journal of vascular surgery.

[30]  Chaoyong James Yang,et al.  Highly parallel single-molecule amplification approach based on agarose droplet polymerase chain reaction for efficient and cost-effective aptamer selection. , 2012, Analytical chemistry.

[31]  Jesse V Jokerst,et al.  Nanoparticle PEGylation for imaging and therapy. , 2011, Nanomedicine.

[32]  J. Sutcliffe,et al.  Fully automated preparation of n.c.a. 4-[18F]fluorobenzoic acid and N-succinimidyl 4-[18F]fluorobenzoate using a Siemens/CTI chemistry process control unit (CPCU). , 2007, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[33]  L. Sobin,et al.  TNM classification of malignant tumors, fifth edition (1997) , 1997, Cancer.

[34]  C. Wood,et al.  Therapeutic peptides: technological advances driving peptides into development. , 2006, Current opinion in biotechnology.

[35]  O. Garden,et al.  Surgical resection of hepatic metastases from colorectal cancer: A systematic review of published studies , 2006, British Journal of Cancer.

[36]  Sanjiv S Gambhir,et al.  A molecular imaging primer: modalities, imaging agents, and applications. , 2012, Physiological reviews.

[37]  Kemin Wang,et al.  Selection of aptamers for molecular recognition and characterization of cancer cells. , 2007, Analytical chemistry.

[38]  R. Blasberg.  Molecular imaging and cancer. , 2003, Molecular cancer therapeutics.